The Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA

Clinical trial pipeline · Data from ClinicalTrials.gov

See which The Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

All recent trials (1 shown)

UnknownPhase 2

NCT05914714

Ruxolitinib as GVHD Prophylaxis in AA Patients

Our study aimed to determine the prophylactic value of ruxolitinib for aGVHD in HSCT recipients of AA.Ruxolitinib was initiated at the beginning of conditioning…

Location not specified46 participantsStarted 2023-07-01

Treatment: Ruxolitinib 5 MG BID Oral Tablet